Patrick Gleason, Pharm.D., of Prime Therapeutics was named a 2026 PBMI Innovator for his work on cost-effective formulary strategy and real-world evidence generation.
Mostafa Kamal, chief executive officer at Prime Therapeutics, shares why the key question in the drug pricing debate is not just where health care value is created, but whether it ultimately reaches the patients, employers and health plans paying for care.
Zach Jones, Pharm.D., is senior director of clinical formulary strategy, Prime Therapeutics, a Minnesota-based pharmacy benefit manager.
AMCP 2026 spotlighted oncology innovation, AI, and payer strategies, with KOL insights on cost, access, and evolving managed care trends.
Managed Healthcare Executive
Managed Healthcare Executive
Experts from AMCP emphasize the importance of drug-adjacent early detection tests and screening ability to improve patient outcomes.
Experts from AMCP discuss the real-world evidence on GLP-1 usage and health care spending.
Specialty Pharmacy Continuum
Ben Urick, PharmD, PhD, examines GLP-1 coverage gaps and real-world evidence challenges shaping payer decisions and obesity treatment access
Abby Kim, PharmD, delves into oncology trends, biomarker testing gaps, and evolving clinical pathways shaping precision care and treatment decisions
At the AMCP Annual Meeting this week, experts from Prime Therapeutics said virtual navigation and clinical pathways are helping lower acute care use, guide treatment decisions and improve outcomes for patients with cancer
Login Portals
Compliance / Legal
Company
